Spero Therapeutics (MEX:SPRO) Depreciation, Depletion and Amortization: MXN0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SPRO Spero Therapeutics Inc MEX:SPRO
40 GF Score
Price MXN20.74
GF Value MXN13.54
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Spero Therapeutics Depreciation, Depletion and Amortization?

Spero Therapeutics MEX:SPRO 40 Depreciation, Depletion and Amortization is MXN0.0 Mil as of Jun. 2026. GuruFocus rates MEX:SPRO with a GF Score™ of 40/100 and a GF Value™ of MXN13.54 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Spero Therapeutics's depreciation, depletion and amortization for the three months ended in Jun. 2026 was MXN0.0 Mil. Its depreciation, depletion and amortization for the trailing twelve months (TTM) ended in Jun. 2026 was MXN0.0 Mil.


Spero Therapeutics  (MEX:SPRO) Depreciation, Depletion and Amortization Explanation

One of the key tenets of Generally Accepted Accounting Principles (GAAP) is the matching principle. The matching principle states that companies should report associated costs and benefits at the same time.

For example:

If a company buys a $300 million cruise ship in 1982 and then sells tickets to passengers for the next 30 years, the company should not report a $300 million expense in 1982 and then ticket sales for 1982 through 2012. Instead, the company should spread the purchase price of the ship (the cost) over the same time period it sells tickets (the benefit).

To create income statements that meet the matching principle, accountants use an expense called depreciation.

So, instead of reporting a $300 million purchase expense in 1982, the company might:

Report a $30 million depreciation expense in 1982, 1983, 1984...and every year after that for the 30 years the company expects to sell tickets to passengers on this cruise ship.

To calculate depreciation, a company must make estimates and choices such as:

The cost of the asset
The useful life of the asset
The salvage value of the asset at the end of its useful life
And a way of spreading the cost of the asset to match the time when the asset provides benefits

The range of different ways of spreading the cost under GAAP accounting is too long to list. However, public companies in the United States explain their depreciation choices to shareholders in a note to their financial statements. It is critical that investors read this note. Investors can find this note in the company's 10-K.

Past depreciation expenses accumulate on the balance sheet. Most public companies choose not to show this contra asset account on the balance sheet they present to shareholders. Instead, they simply show a single item. This single asset item may be marked Net. Such as Property, Plant, and Equipment - Net. It is actually the asset account netted against the contra asset account.

A contra asset account is an account that offsets an asset account. So, for example a company might have:

Property, Plant, and Equipment - Gross: $150 million
Accumulated Depreciation: $120 million
Property, Plant, and Equipment - Net: $30 million

In this case, the only item likely to be shown on the balance sheet is Property, Plant, and Equipment - Net. This is the cost of the company's property, plant, and equipment (asset account) minus the accumulated depreciation (the contra asset account). It means the company's assets cost $150 million, the company has reported $120 million in depreciation expense over the years, and the company is now reporting the assets have a book value of $30 million.

It is possible for a company to have fully depreciated assets on its balance sheet. This means the company's estimate of the useful life of the asset was shorter than the asset's actual useful life. As a result, the asset - although it is still being used - is carried on the balance sheet at its salvage value.

This is a reminder that depreciation involves estimates and choices. It is not an infallible process.

Companies do not have cash layout for depreciation. Therefore, depreciation is added back in the cash flow statement.

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when it purchases them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because depreciation is not included as an expense. Warren Buffett even jokingly said We prefer earnings before everything when criticizing the abuse of EDITDA.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Spero Therapeutics Depreciation, Depletion and Amortization Related Terms


Spero Therapeutics Depreciation, Depletion and Amortization Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Depreciation, Depletion and Amortization can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Depreciation, Depletion and Amortization Chart

Spero Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Depreciation, Depletion and Amortization
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.25 16.94 6.23 0.04 0.00

Spero Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Depreciation, Depletion and Amortization Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:SPRO
40GF Score
Spero Therapeutics Inc MEX:SPRO
Depreciation, Depletion and Amortization is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics Depreciation, Depletion and Amortization Calculation

Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.

Depletion and amortization are synonyms for depreciation.

Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Depreciation, Depletion and Amortization of MXN0.0 Mil mean?
Spero Therapeutics (MEX:SPRO) has a Depreciation, Depletion and Amortization of MXN0.0 Mil as of Jun. 2026. Depreciation, depletion and amortization is the amount accounted for the decline in value of long-term assets. View historical data on Spero Therapeutics.
Is Spero Therapeutics' Depreciation, Depletion and Amortization too high?
Spero Therapeutics' current Depreciation, Depletion and Amortization is MXN0.0 Mil. Overall, Spero Therapeutics has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Depreciation, Depletion and Amortization compare to ?
Spero Therapeutics' Depreciation, Depletion and Amortization of MXN0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Depreciation, Depletion and Amortization for a Biotechnology company?
A good Depreciation, Depletion and Amortization depends on the Biotechnology industry context. However, Depreciation, Depletion and Amortization should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Depreciation, Depletion and Amortization mean?
A high Depreciation, Depletion and Amortization can signal that a stock is expensive relative to its fundamentals. Depreciation, depletion and amortization is the amount accounted for the decline in value of long-term assets. View historical data on Spero Therapeutics. Spero Therapeutics's current Depreciation, Depletion and Amortization is MXN0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (MEX:SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN13.54, compared to a current price of MXN20.74 — trading 53.2% above its estimated fair value. The current Depreciation, Depletion and Amortization is MXN0.0 Mil. Spero Therapeutics' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Depreciation, Depletion and Amortization calculated?
Depreciation, Depletion and Amortization is calculated from a company's financial statements. For Spero Therapeutics (MEX:SPRO), the current Depreciation, Depletion and Amortization is MXN0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (MEX:SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of MXN20.74 is trading 53.2% above its estimated GF Value™ of MXN13.54. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for MEX:SPRO:

  • Depreciation, Depletion and Amortization: MXN0.0 Mil
  • GF Value™: MXN13.54 vs. price of MXN20.74 (53.2% above fair value)
  • GF Score™: 40/100 with 2 warning signs

No single metric tells the full story. See the MEX:SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Spero Therapeutics Business Description

Comparable Companies
Other Exchanges SPRO:USA2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
40GF Score

Get the complete analysis for MEX:SPRO

Depreciation, Depletion and Amortization is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN20.74
Price
MXN13.54
GF Value